Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04363684 · ClinicalTrials.gov registry record

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

A clinical trial of Amyotrophic Lateral Sclerosis and Progressive Supranuclear Palsy (PSP), sponsored by Mayo Clinic.

Recruiting
Registry status
2,100
Enrollment target
20
Study locations

NCT04363684: Recruiting study of Amyotrophic Lateral Sclerosis and Progressive Supranuclear Palsy (PSP), sponsored by Mayo Clinic.

NCT04363684 is a study of Amyotrophic Lateral Sclerosis and Progressive Supranuclear Palsy (PSP) that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 2,100 participants, above the 877-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (139% higher). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04363684, a study of Amyotrophic Lateral Sclerosis and Progressive Supranuclear Palsy (PSP), is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
2,100 participants
Enrollment target
20
Study locations

Study Summary

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.

Primary Outcome

Compare rates of change in whole brain and regional volumes between asymptomatic f-FTLD and symptomatic f- and s-FTLD, measured using MRI.

Conditions Studied

Amyotrophic Lateral Sclerosis Progressive Supranuclear Palsy (PSP) Corticobasal Degeneration (CBD) Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Semantic Variant Primary Progressive Aphasia (svPPA) C9orf72 Frontotemporal Lobar Degeneration (FTLD) Behavioral Variant Frontotemporal Dementia (bvFTD) FTD With Amyotrophic Lateral Sclerosis (FTD/ALS) Oligosymptomatic PSP (oPSP)

Study Locations (20)

California

  • University of California, Los Angeles - Los Angeles
  • University of California, San Diego - San Diego
  • University of California San Francisco - San Francisco

Maryland

  • Johns Hopkins University - Baltimore
  • NIH - Bethesda

New York

  • Mount Sinai - New York
  • Columbia University - New York

Alabama

  • University of Alabama Birmingham - Birmingham

Colorado

  • University of Colorado Denver - Denver

Florida

  • Mayo Clinic Florida - Jacksonville

Georgia

  • Emory University - Atlanta

Illinois

  • Northwestern University - Chicago

Trial Details

FieldValue
Enrollment Target 2,100 participants
Start Date 2020-03-01
Est. Completion 2026-06-30
Mayo Clinic

2,844 total trials

What NCT04363684 shows while recruiting

NCT04363684 is an observational study that tracks outcomes without assigning an intervention. Its 2,100 participants enrollment target places it among the larger protocols in the corpus, above the 877-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (139% higher).

The record links to 10 conditions, with Amyotrophic Lateral Sclerosis appearing as the primary indexed condition, and to 0 interventions.

NCT04363684 names 20 study sites across 16 states, led by California, Maryland, New York.

Frequently Asked Questions

What is clinical trial NCT04363684 about?

NCT04363684 is a clinical study titled "ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)". ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.

What is the current status of trial NCT04363684?

This trial is currently recruiting. The enrollment target is 2,100 participants. The study started on 2020-03-01. Estimated completion is 2026-06-30.

What conditions does trial NCT04363684 study?

This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis, Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), Semantic Variant Primary Progressive Aphasia (svPPA).

Who is sponsoring clinical trial NCT04363684?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04363684 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Amyotrophic Lateral Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04363684's enrollment target sits among peer trials

2,100 6th of 102 higher than 97 of 102 other Amyotrophic Lateral Sclerosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Amyotrophic Lateral Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04649242 · 2,100 participants · Phase 3

    Randomized Study in Children and Adolescents With Migraine: Acute Treatment

  • NCT05206331 · 2,100 participants · Phase 4

    CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study

  • NCT05270499 · 2,100 participants

    Aveir VR Real-World Evidence Post-Approval Study

  • NCT06324981 · 2,100 participants · NA

    Using AI Text Messaging to Improve AHA's Life's Essential 8 Health Behaviors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT04363684

Source: ClinicalTrials.gov NCT04363684, the US trial registry maintained by the National Library of Medicine. NCT04363684 (large enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.